aTyr Pharma (Nasdaq: ATYR) announced topline results from its Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. The study did not meet its primary endpoint of change in mean daily oral corticosteroid dose at week 48, with a reduction to 2.79 mg for efzofitimod vs 3.52 mg for placebo (p=0.3313). However, …
Read More »aTyr Pharma’s Phase 3 Sarcoidosis Drug Misses Primary Endpoint
